ArticleCureus2026
Primary Ovarian Angiosarcoma: A Case Report and Review of the Literature.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiosarcomas are rare sarcomas with a poor prognosis, and treatment modalities are still being established. Cutaneous and soft tissue angiosarcomas are frequently reported; however, those occurring at rare sites have fewer published case reports and series. An unusual case was encountered at our institute: a 25-year-old woman with an ovarian tumor in which angiosarcoma was diagnosed in a background of teratoma. The details of surgery, gross appearance, histopathological findings, and immunohistochemistry (IHC) workup leading to the diagnosis are presented, along with a review of the current literature. The ease of reaching the histological diagnosis of angiosarcoma depends on the site of occurrence and degree of differentiation. Recent advances in therapeutics, along with emerging evidence from clinical trials, have demonstrated promising outcomes in the treatment of angiosarcoma. It is possible to reach an accurate diagnosis by keeping in mind its histological variability and key histologic features and by performing an appropriate IHC workup. Improving treatment results for patients with angiosarcoma involves a shift toward multimodal therapy and precision medicine, and recent breakthroughs offer hope for better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.